Cargando…
Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor
The spiroindolones, a new class of antimalarial medicines discovered in a cellular screen, are rendered less active by mutations in a parasite P-type ATPase, PfATP4. We show here that S. cerevisiae also acquires mutations in a gene encoding a P-type ATPase (ScPMA1) after exposure to spiroindolones a...
Autores principales: | Goldgof, Gregory M., Durrant, Jacob D., Ottilie, Sabine, Vigil, Edgar, Allen, Kenneth E., Gunawan, Felicia, Kostylev, Maxim, Henderson, Kiersten A., Yang, Jennifer, Schenken, Jake, LaMonte, Gregory M., Manary, Micah J., Murao, Ayako, Nachon, Marie, Murray, Rebecca, Prescott, Maximo, McNamara, Case W., Slayman, Carolyn W., Amaro, Rommie E., Suzuki, Yo, Winzeler, Elizabeth A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904242/ https://www.ncbi.nlm.nih.gov/pubmed/27291296 http://dx.doi.org/10.1038/srep27806 |
Ejemplares similares
-
Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model
por: Lakshminarayana, Suresh B., et al.
Publicado: (2015) -
A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609
por: Zhang, Rou, et al.
Publicado: (2016) -
A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
por: Leong, F. Joel, et al.
Publicado: (2014) -
Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria
por: Schmitt, Esther K, et al.
Publicado: (2021) -
Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa
por: Ndayisaba, Gilles, et al.
Publicado: (2021)